Inaugurational lecture Prof. Dr. Willem Mulder - Cardiovascular Nanomedicine
Summary of Prof. Dr. Willem Mulder #39;s inauguration lecture - Cardiovascular Nanomedicine: A small solution for a big problem. University of Amsterdam (UvA) - ...
By: High on Nano
Link:
Inaugurational lecture Prof. Dr. Willem Mulder - Cardiovascular Nanomedicine - Video
A new type of micromotor has been developed. Directed by magnets and powered by ultrasound, these micromotors are capable of traveling across microscopic particles and cells in very crowded areas without causing any damage.
These microswimmers provide a new way to manipulate single particles with precise control and in three dimensions, without having to do special sample preparation, labeling, surface modification, said Joseph Wang, a professor of nanoengineering at University of California San Diego (USCD), in a UCSD press release.
Wang, Thomas Mallouk, a professor of chemistry at the University of Pennsylvania, and Wei Wang, professor of materials science and engineering at Harbin Institute of Technology, are credited as senior authors of a paper detailing the development of these micromotors. The study was published on Oct. 25 in Science Advances.
Researchers tested the technology by moving HeLa cells the oldest and most commonly used cell line for scientific research and silica particles in aqueous media with micromotors. They accomplished this task without damaging nearby particles and cells. In one test, the researchers were able to create letters by pushing particles with the micromotors. In another, they exerted control over the micromotors, making them climb up microscopic blocks and stairs. This test demonstrated that they were capable of navigating over three-dimensional objects.
The micromotors are essentially gold-coated hollow polymer structures that are shaped like a half capsule. Within the body of the micromotor is a tiny magnetic nickel nanoparticle, allowing them to be steered with magnets. The inside surface is treated so it can repel water, so when the micromotor is submerged in water, an air bubble is trapped inside the device. This trapped bubble is integral to the functioning of the micromotor, as it allows the micromotor to respond to ultrasound. Upon receiving ultrasound waves, the trapped bubble begins to oscillate, forming forces that give it an initial push to movement. By applying an external magnetic field, it can move continuously, while altering the direction of the field allows researchers to control the speed and trajectory of the micromotors.
We have a lot of control over the motion, unlike a chemically fueled micromotor that relies on random motion to reach its target, said Fernando Soto, a nanoengineering Ph.D. student studying at UC San Diego. Also, ultrasound and magnets are biocompatible, making this micromotor system attractive for use in biological applications.
The authors plan on making improvements to the micromotors in the coming years. For example, they want to make them more biocompatible using biodegradable polymers and a magnetic material that is less toxic, such as iron oxide. Thanks to this technology, the researchers have opened new possibilities for nanomedicine, tissue engineering, targeted drug delivery, regenerative medicine, and other applications in the field of biochemistry.
Read more:
Micromotors move single cells using magnets and ultrasound - CMU The Tartan Online
Overview:
Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.
Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.
Get Enquiry More About This Report:https://www.trendsmarketresearch.com/report/sample/9807
Market Analysis:
The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.
The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.
Regional Analysis:
The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.
Therapeutic Application Analysis:
Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market.
Get Request for Discount:https://www.trendsmarketresearch.com/report/discount/9807
The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.
Key Players:
Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.
Competitive Analysis:
At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Benefits:
The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Read this article:
Nanomedicine Market Sales Revenue to Significantly Increase in the Next Few Years - Crypto News Byte
SHELTON, Conn., June 26, 2017 /PRNewswire/ --NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its poster entitled "Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture" will be presented today at the 36th Annual Meeting of the American Society of Virology (ASV). The poster will be presented in Poster Session II, open for viewing from 4pm to 6pm today, Monday, June 26th, 2017. The ASV Meeting is being hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 (https://extensionconferencecenters.uwex.edu/asv2017/).
Dr. Brian Friedrich, Senior Virologist of the Company, is presenting the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3) in this poster.
The two active nanoviricide candidates presented here inhibited VZV up to 5x better than acyclovir-sodium (the current standard of care), and completely inhibited VZV protein production/infection in cell culture studies. These results indicate a very high level of anti-VZV effectiveness.
The nanoviricide candidates were non-cytotoxic even at the highest doses in all cell lines tested. Thus it should be possible to administer very high concentrations of the drug locally on the skin without any deleterious effects.
Importantly, the data being presented demonstrate that the anti-viral activity of a nanoviricide is driven by the virus-specific ligand attached to it. Thus two of the nanoviricide drug candidates were highly effective against VZV, whereas a third one was not as effective. All three ligands were derived by in silicon computer-aided drug design based on known structures of HSV glycoprotein binding to the cellular receptor, namely the herpesvirus entry mediator (HVEM), and thus were expected to be active against herpes simplex viruses, and some of them were anticipated to be active against all alphaherpesviruses. VZV is an alphaherpesvirus.
Varicella Zoster virus (VZV) primary infection causes chickenpox, followed by latency in ganglia and neurons, and can reactivate decades later causing herpes zoster (shingles), usually upon immunosuppression resulting from age, stress, or other factors. Classical shingles presents as a painful unilateral dermatomal vesicular rash as virus spreads to the skin through peripheral nerves. In severe cases, VZV can reactivate in or around the eye which can cause facial disfiguration or blindness. There are about 1 million cases annually and the lifetime risk of developing shingles is at least 30%. While there is a shingles vaccine, it is not effective post-breakout, is only ~50% effective in preventing disease, and cannot be given to immunosuppressed people.
Topical treatment of shingles remains an unmet medical need, and would enable high concentration of active drug locally for rapid treatment with minimal systemic effects. NanoViricides, Inc. is developing broad-spectrum drugs against herpesviruses for both topical and systemic use. Our novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles by specially designed small chemical ligands and dismantle them with the polymeric micelle which is covalently attached. Our approach of designing ligands to mimic virus binding sites on cellular receptors promises that a virus cannot escape the nanoviricide drug due to mutation(s).
NanoViricides, Inc. is advancing these candidates further into ex vivo dermal studies towards IND filing. The Company has already initiated anti-VZV effectiveness studies for these drug candidates in an ex vivo human skin-patch model developed by Dr. Jennifer Moffat at the State University of New York, Upstate Medical University, Syracuse, NY. The Company intends to release the data from these studies as they become available.
The poster is available for viewing on the Company's website (www.nanoviricides.com).
About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission.. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
SOURCE NanoViricides, Inc.
View original post here:
NanoViricides' Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be ... - satPRnews (press release)
Market share of global Nanomedicine industry is dominate by companies like Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018).
Access Report Details at:https://www.themarketreports.com/report/global-nanomedicine-market-by-manufacturers-countries-type-and-application-forecast
Market Segment by Regions, regional analysis covers:
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers:
Quantum dots
Nanoparticles
Nanoshells
Nanotubes
Nanodevices
Market Segment by Applications, can be divided into
Segmentation encompasses oncology
Infectious diseases
Cardiology
Orthopedics
Others
Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1490823
With the help of 15 chapters spread over 100 pages this report describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Nanomedicine, in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2019 to 2024 is provided in this research report. At last information about Nanomedicine sales channel, distributors, traders, dealers, and research findings completes the global Nanomedicine market research report.
Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1490823
Read the original here:
Global Nanomedicine Market by Types, Applications, Countries, Companies and Forecasts to 2024 covered in a Latest Research - Market Research Newspaper
The new report by Expert Market Research titled, GlobalBuilding-Integrated Photovoltaics MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global building-integrated photovoltaics market, assessing the market based on its segments like technology, application, end use, and major regions like Asia Pacific, Europe, North America, Middle East and Africa and Latin America. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.
Request a free sample copy in PDF or view the report [emailprotected]https://www.expertmarketresearch.com/reports/building-integrated-photovoltaics-market/requestsample
The key highlights of the report include:
Market Overview (2016-2026)
The growth of the global building-integrated photovoltaic system is driven by the shifting trend towardsrenewable energysources. The increasing utilisation ofsolar energysolutions globally along with increasing sustainability in supply chains is expected to bolster the market growth. Additionally, the rising awareness for green building and zero-emission structures is anticipated to bolster the market growth. Moreover, the research and development activities in the renewable energy sources will likely push the growth further. However, the reduction of effectiveness of BIPV systems due to high initial cost and limitation of solar energy such as intermittency and shadows may constrain the growth over the forecast period.
Industry Definition and Major Segments
A building-integrated photovoltaic (BIPV) system refers to an important component of the building skin utilised in converting solar energy intoelectricityalong with protecting the structure from the environmental elements. BIPV is one of the fastest growing segments of the solar photovoltaic industry.
Explore the full report with the table of [emailprotected]https://www.expertmarketresearch.com/reports/building-integrated-photovoltaics-market
Based on technology, the global building-integrated photovoltaics market can be divided into:
Building-integrated photovoltaics market on the basis of application can be divided into:
The industry based on end use, is categorised into:
The regional markets for building-integrated photovoltaics include:
Market Trends
Regionally, Europe is expected to hold the largest share in terms of installed capacity in the global market for building-integrated photovoltaic systems. This can be attributed to due to stringent environmental regulations policies, higher customer willingness to adopt environmental-friendly practices, along with increasing pressure for reducing net energy consumption from buildings. Additionally, the EUs target to achieve 27% share for renewable energy consumption is anticipated to increase the growth further. Meanwhile, North America is expected to show a significant growth over the forecast period due to increasing awareness for the integration renewable energy sources.
Key Market Players
The major players in the market are AGC Solar, Belectric, Heliatek GmbH, Carmanah Technologies, Corporation, Dyesol Ltd. (Greatcell Solar Limited), Hanergy Holding Group Limited, Ertex solartechnik GmbH, and few others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Read More Reports:
Global Collagen Market:https://www.expertmarketresearch.com/reports/collagen-market
Global Biologics Market:https://www.expertmarketresearch.com/reports/biologics-market
Global Nanomedicine Market:https://www.expertmarketresearch.com/reports/nanomedicine-market
Global Mixed Reality Market:https://www.expertmarketresearch.com/reports/mixed-reality-market
About Us:
Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.
At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.
We also provide state-of-the-art procurement intelligence through our platform,https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.
Informes de Expertos (https://www.informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.
Determined to bring client satisfaction, we make sure that our tailored approach meets the clients unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.
Media Contact
Company Name: EMR Inc.Contact Person: Steven Luke, Corporate Sales Specialist U.S.A.Email:[emailprotected]Toll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite:https://www.expertmarketresearch.com
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
Content Source @https://takeitcool.com/global-building-integrated-photovoltaics-market-size-share-key-players-demand-growth-analysis-research-report/
Continue reading here:
Global Building-Integrated Photovoltaics Market To Be Driven At A CAGR Of 9% In The Forecast Period Of 2021-2026 - Digital Journal
magforce - Using advanced nanomedicine for innovative therapies
Extending the role of nanomedicine in cancer treatment Every year, more than 10 million people worldwide are diagnosed with cancer for the first time. The Wo...
By: Magforce AG
Follow this link:
magforce - Using advanced nanomedicine for innovative therapies - Video
Healthcare Nanotechnology (Nanomedicine) Market report provides profound research of industry players, dynamics, and strategies are segmented and sub-segmented to simplify the actual conditions of the industry. The report also covers scope of product market, research methodology, Porters Five Force analysis, and Competitive landscape of industry. This report scrutinizes all the key factors influencing growth of global Healthcare Nanotechnology (Nanomedicine) market, including production and value chain analysis, pricing structure, demand-supply scenario, profit margins.
Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14099195
Top Players Are:
Key Market Trends:
The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period
A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.
Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.
North America is Expected to Hold the Largest Share in the Market
In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.
For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195
Market Overview:
Report Highlights:
Scope of the Report:
As per the , the healthcare nanotechnology (nanomedicine) market includes products that are nanoformulations of the existing drugs or new drugs or are nanobiomaterials. The market is segmented by its application in the medical field, as drug delivery, biomaterials, active implants, diagnostic imaging, tissue regeneration, and other applications. The market is also segmented by its use in the treatment of diseases, like cardiovascular diseases, oncological diseases, neurological diseases, orthopedic diseases, infectious diseases, and other diseases.<
Competitive Landscape:
Most of the companies present in the market are efficient at the technological front, but require significant support for enhancing their services and expanding their businesses. Thus, mergers and acquisitions offer significant opportunities to gain the attention of a large number of providers across developed regions.
Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14099195
Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market Report 2024:
1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Contact Us:
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [emailprotected]
Our Other Reports:
Tea-filled Tin Market Size and Share Analysis 2021 Opportunities in Grooming Regions, Worldwide Growth Survey, Market Trends, and Company Overview with Covid-19 Impact till 2026
Developers Kits Market Size and Share Analysis 2021 Opportunities in Grooming Regions, Worldwide Growth Survey, Market Trends, and Company Overview with Covid-19 Impact till 2026
Testing, Inspection, and Certification Market Size with Share 2021 Opportunities and Future Trends, Investment Analysis, Growth Overview of Top Companies and Global Forecast Analysis till 2024
Big Data Analytics in Manufacturing Industry Market Size with Share 2021 Opportunities and Future Trends, Investment Analysis, Growth Overview of Top Companies and Global Forecast Analysis till 2024
Euro Container Market Size and Share Analysis 2021 Opportunities in Grooming Regions, Worldwide Growth Survey, Market Trends, and Company Overview with Covid-19 Impact till 2026
Particulate Filters Market Analysis with Impact of Covid-19 on Industry Size 2020 | Future Growth and Challenges by Manufacturers and Marketing Strategy Forecast to 2026 | Industry Research.co
Non Licensed Sports Merchandise Market Size and Development Trends Analysis 2021: Global Opportunities and Strategic Movement by Players, Revenue, Share and Innovations Forecast to 2026
Floor Saw Cutting Equipment Market Growth Analysis by Size 2021: Report Outline Major Key Players, Development Plans, Global Share, Business Opportunities and Drivers Forecast to 2026
L-Cysteine and Its Hydrochloride Market Size and Development Trends Analysis 2021: Global Opportunities and Strategic Movement by Players, Revenue, Share and Innovations Forecast to 2026
Cisatracurium Besylate Injection Market 2020 with Global Industry Size and Share, Future Growth Rate, Leading Players Analysis, Trending Technologies, Business Strategies Forecast to 2026
Rotor Spinning Machinery Market Size, Share Analysis 2020 Global Analysis by Key Players, Growth Overview, Type and Applications by Regions Forecast to 2025 | Industry Research.co
Home Use WiFi Router Market Revenue, Business Growth 2020: Demand and Applications, Business Statistics, Competitors Strategy, Size, Share Forecast to 2026 | Industry Research.co
See the original post:
Healthcare Nanotechnology (Nanomedicine) Market Competition by Companies and Countries, Industry Chain Structure, Shares, Supply, Demands,...
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-
-Publication Further Supports Capricors Exosome Platform Advancement-
LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today the publication, in collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency. The publication titled, Small molecule inhibitors and culture conditions enhance therapeutic cell and EV potency via activation of beta-catenin and suppression of THY1 was published in the international peer-reviewed journal, Nanomedicine: Nanotechnology, Biology and Medicine.
This data from this publication is of significant importance to Capricor because it demonstrates our approach to enhance potency of cells by targeting select signaling pathways. The ability to manipulate cells provides read through to our exosome product candidates which are being engineered to treat specific diseases. We have dedicated the last few years at Capricor to understanding the molecular composition of our exosomes products in order to identify microRNAs of interest for therapeutic development, said Dr. Linda Marbn, Ph.D., CEO of Capricor. This data was the foundation of our new platform, which has allowed us to expand our reach to engineering exosomes that contain RNAs for targeted therapeutic delivery. Further, this elucidation of the mechanisms that are driving potential potency of our cell therapy, CAP-1002 and the exosomes they secrete, correlate to some of the promising clinical data we have seen to date in Duchenne muscular dystrophy.
Key findings include:
Dr. Marbn continued, We know that the exosome is natures delivery system and can serve to carry a variety of biologic signals directly to the cell. Now, we have demonstrated that cells can make exosomes loaded with specific and powerful biologic signals. From these early studies, we have launched our platform which will include vaccines, treatment of monogenic diseases, as well as other targets. We plan to announce further pipeline expansion of our exosome-based product candidates by mid-2021.
The work at Cedars-Sinai Medical Center was supported by NIH R01124074; work by Capricor was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-1-0712. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.For more information, visitwww.capricor.comand follow the Company onFacebook,InstagramandTwitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on November 13, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricors exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Media Contact:Caitlin Kasunich / Raquel ConaKCSA Strategic Communicationsckasunich@kcsa.com/ rcona@kcsa.com212.896.1241 / 212.896.1204
Investor Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com617.435.6602
Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com310.358.3200
Read more from the original source:
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - GlobeNewswire
The MarketWatch News Department was not involved in the creation of this content.
Jul 29, 2020 (The Expresswire) --Global Healthcare Nanotechnology (Nanomedicine) Market Report 2020 (value and volume) by company, regions, product types, end industries, history data and estimate data. Also, Report contains a comprehensive analysis of the important segments like market opportunities, import/export details, market dynamics, key manufacturers, growth rate, and key regions. This report focuses on the Healthcare Nanotechnology (Nanomedicine) in the Global market, especially in the United States, Europe, China, Japan, South Korea, North America, India.Healthcare Nanotechnology (Nanomedicine) Market report categorizes the market based on manufacturers, regions, type, and application. Healthcare Nanotechnology (Nanomedicine) Market reports offer a detailed assessment of the Healthcare Nanotechnology (Nanomedicine) including enabling technologies, current market situation, market assumptions, restraining factors.
The Global Healthcare Nanotechnology (Nanomedicine) market swot is provided for the international markets including progress trends, competitive landscape breakdown, and key in regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.
TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT - REQUEST SAMPLE
The global healthcare nanotechnology market was valued at USD 156.56 billion in 2017. This market is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2017. North America dominates the market, and is expected to maintain its position over the forecast period.
Rising applications in Oncology
Nanomedicine is a promising mode of cancer treatment and has several applications in oncology. Cancer has a major impact on United States and across the world. As per WHO, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million were the cancer-related deaths. Therefore the demand for nanomedicine in the market was in order to curb such high incidence rate and is expected to boost market. Researchers have been working on improvisation of techniques, to deliver chemotherapeutic agents precisely at the Nano level in tumorous tissues. Nanoscale objects are used by themselves or as parts of larger devices containing multiple nanoscale objects and due their small size, nanoscale devices can readily interact with the biomolecules on both the surface and the inner cells and they have the potential to diagnose and treat cancer. Nanoparticles are majorly been used as nanocarriers, to deliver the cytotoxic drugs to the tumor cells and tissues. The increasing incidence of cancer and importance of nanomedicine in modern cancer treatment procedures, are expected to drive the nanomedicines demand during the forecast period.
Huge costs of the medical devices
Cost is the main factor that is often overlooked, which is specifically important in the face of ever increasing healthcare cost and unpredictable reimbursement environment. Nanomedicines are no different; there are several FDA approved nanoparticle-based products in the market, which can be compared with their non-nanoparticle based counterparts. Although these formulations may be more efficient and less toxic than their counterparts, their costs may also be significantly high. The average cost per dose of anticancer drug doxorubicin is about USD 62-162, compared to USD 5,594 for Doxil, which is a nanoparticle containing doxorubicin. Similarly, the average cost per dose of anticancer drug Abraxane, a paclitaxel nanoformulation, is USD 5,054. Therefore, owing to the inability of the industry to find a cost-effective method of scaling up the production, the cost of nanomedicine therapies is likely to remain high over the forecast period. This high cost of nanoparticle-assisted medicine, relative to its traditional counterparts, is hindering the growth of the market.
US Healthcare Nanotechnology Market
The US-based pharmaceutical companies believe that nanomedicines is the next big thing, as it has been opening up newer and has more accurate options for the target drug delivery, and resulting in very few side effects. The Swiss Groups Kadcyla received the approval of the United States in February 2017. The product treats breast cancer with very less side-effects. In addition with the booming RandD, United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in healthcare. Owing to the large geriatric population, increasing need for diagnostics, growing need of augmented cancer therapies, government initiatives, and increasing awareness of nanomedicines, the US healthcare nanotechnology sector will witness substantial growth during the forecast period.
The key players in the market are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS Inc., JOHNSON and JOHNSON, MALLINCKRODT Plc, MERCK and COMPANY, Inc., NANOSPHERE, Inc., PFIZER, and CELGENE CORPORATION.
Get a Sample PDF of Report @https://www.360marketupdates.com/enquiry/request-sample/12884242
The global Healthcare Nanotechnology (Nanomedicine) market covers the vision of participant analysis by product types, market share, applications, sales, and revenue.
Healthcare Nanotechnology (Nanomedicine) Market Report covers the Top Key-players in 2020:-
Highlighted points of Healthcare Nanotechnology (Nanomedicine) Market Size:
Inquire more and share questions if any before the purchase on this report@https://www.360marketupdates.com/enquiry/pre-order-enquiry/12884242
This Healthcare Nanotechnology (Nanomedicine) Market Research/analysis Report Contains Answers to your following Questions
Key Developments in the Healthcare Nanotechnology (Nanomedicine) Market:
Reasons to Purchase this Report
Purchase this report (Price 4250 USD for a single-user license)@https://www.360marketupdates.com/purchase/12884242
Finally, the report Global Healthcare Nanotechnology (Nanomedicine) Market 2020 describes the Healthcare Nanotechnology (Nanomedicine) industry expansion game plan, the Healthcare Nanotechnology (Nanomedicine) industry knowledge supply, appendix, analysis findings, and the conclusion.
About 360 Market Updates:
360 Market Updates is a credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is to provide a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision-makers in finding the most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.
Contact Info: -
360 Market Updates
Mr. Ajay More
USA: +1 424 253 0807
UK: +44 203 239 8187
CHECK OUT OUR OTHER RELATED REPORTS:-
Ultracentrifuge Market Size 2020: Industry Size, Share, Future Challenges, Revenue, Demand, Industry Growth and Top Players Analysis to 2025
Global Data Center Construction Market Size 2020 Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast to 2024
Linear Stepper Motors Market 2020 -Key Leaders Analysis, Segmentation, Growth, Future Trends, Gross Margin, Demands, Emerging Technology by Regional Forecast to 2026 - 360 Market Updates
Mill Rolls Market Trends, Size, Share, Growth, Top Manufacturers, Recent Development and Forecast by 2026 | 360 Market Updates
Depyrogenated Sterile Empty Vials Market Size, Share, Growth, Top Manufacturers, Recent Development and Forecast by 2026 | 360 Market Updates
Big Data in Oil and Gas Exploration and Production Market 2020 Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2020-2024 By 360 Market Updates
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Global Healthcare Nanotechnology (Nanomedicine) Market Top Countries Data 2020 Industry Size Analyzed by Business Opportunity, Development, Growth Factors, Applications Analysis and Future Prospects By 360 Market Updates
COMTEX_368577544/2598/2020-07-29T02:36:40
Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.
The MarketWatch News Department was not involved in the creation of this content.
Read more from the original source:
Global Healthcare Nanotechnology (Nanomedicine) Market Top ...
PALM BEACH, Fla., Nov. 11, 2020 /PRNewswire/ --Academia and industry around the world are working from basic research to advanced technology to alleviate the effects of the COVID19 health crisis. The application of nanoscience and nanotechnology concepts and tools is a good approach within the current global priority. Nanomedicine may provide the fastest-track to the multitude of health issues that are embodied in the global pandemic. Nanotechnology is a common term for nanoscale science, engineering and technology, which offers extraordinary economic and technological benefits. Healthcare is one of the most prominent field of research in nanotechnology. Nanomedicine can be understood as a field of diagnosing, treating and preventing disease using molecular tools and knowledge of the human body. Nanomedicine can address many essential medical problems by using nanomaterials and by obtaining clarity on their interaction with biological systems. Nanomedicine products have various potential applications such as in drug delivery, in vivo imaging, in vitro diagnostics, regenerative medicine, dental, medical devices, and dermal applications. Researchers are turning to nanotechnology to look for answers.Active Biotechs in the markets today include: NanoViricides, Inc. (NYSE: NNVC), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Altimmune, Inc. (NASDAQ: ALT), Eli Lilly and Company's(NYSE: LLY), Pfizer Inc. (NYSE: PFE).
One industry publication (IOPScience) during a report focused on nanotechnology said: "The novel coronavirus pneumonia pandemic was declared as 'public-health emergency of international concern' by the World Health Organization on 30 January 2020. The sudden emergence has triggered alarm for instant management using anti-viral measures and diagnostic tools Taking into consideration the current severity of this disease and the imperative need of SARS-CoV-2 specific treatment and diagnostic tools, nanotechnology-based approaches can provide promising alternatives to conventional ways of disease diagnosis, treatment, and preventing exposure to SARS-CoV-2."
NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today reported that it has engaged Calvert Labs, a contract research organization ("CRO"), for performing the Safety Pharmacology studies of its clinical drug candidate for the treatment of COVID-19.
The Company has been diligently working on advancing its drug candidates for the treatment of COVID-19 towards human clinical trials as rapidly as feasible.
The Company intends to perform certain core safety pharmacology studies to ensure safety of the drug candidates at Calvert Labs. The data from these studies will be used for filing an IND application. Prior to that, the Company also intends to file a pre-IND application with the U.S. Food and Drug Administration ("FDA") to obtain guidance.
The recent increase in COVID-19 cases worldwide has led scientists to suggest that this pandemic virus is expected to become a circulating virus. Influenza viruses and common cold viruses are other examples of circulating viruses. However, SARS-CoV-2 is more virulent, and thereby causes substantially greater morbidity and mortality than these other circulating viruses. Therefore, development of an effective drug to treat the disease caused by SARS-CoV-2 is very important.
A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) the ability of the virus to infect host cells and simultaneously and (ii) the ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies. Read the full press release by going to: http://www.nanoviricides.com/companynews.html
In other biotech news in the markets this week:
INOVIO (NASDAQ: INO) a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, this week reported financial results for the quarter ended September 30, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a clinical program update for its DNA medicines portfolio. The live webcast and a replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.
Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, recently announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID, Altimmune's next-generation, single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia.
Alberto Santagostino, SVP, Head of Cell and Gene Technologies for Lonza, commented, "We are deeply committed to fighting this global pandemic and deploying our expertise and resources to help vaccine developers like Altimmune meet commercial manufacturing requirements for novel and promising vaccine candidates. Lonza is proud to be well-positioned to support these companies in their mission to serve such critical public health needs."
The U.S. Food and Drug Administration (FDA) recently granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) this week announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.
After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: [emailprotected]+1(561)325-8757
SOURCE FinancialNewsMedia.com
See more here:
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments - PRNewswire
Regulatory News:
NANOBIOTIX (Euronext: NANO ISIN: FR0011341205 the Company) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the United States Food and Drug Administration (FDA) has provided Safe to Proceed notifications for two additional trials in its ongoing clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson). These trials were co-developed with Nanobiotix and MD Anderson is the sponsor and executor.
Significant Unmet Needs and Opportunity in Cancer Immunotherapy
Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. However, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). These barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers.
Combining ICIs with radiation therapy is emerging as a valuable strategy to prime an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues.
NBTXR3 is injected one time, directly into solid tumors. The product candidate is designed to increase the energy deposit from radiation therapy within the target tumor and subsequently increase the tumor-killing effect without increasing toxicity in surrounding healthy tissue. Pre-clinical and clinical data also suggest that NBTXR3 activated by radiation therapy can prime the immune system, creating an anti-tumor immune response that produces both local and systemic effects.
A Phase II Study of NBTXR3 Activated by Radiation and Combined with Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Limited PD-L1 Expression or Refractory to PD-1 Blockade
This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objective of the study is to evaluate tumor response of NBTXR3 activated by radiation therapy in combination with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
The population includes patients with inoperable R/M HNSCC of the oropharynx, oral cavity, hypopharynx, larynx or neck. Patients could be anti-PD-1/L1 nave or refractory. Up to 60 patients may be treated, with up to 40 in the first cohort and up to 20 in the second cohort. The first cohort will include anti-PD-1/L1 nave patients with a combined positive score (CPS) between greater than or equal to 1% and less than 20%. The second cohort will include anti-PD-1/L1 refractory patients irrespective of PD-L1 expression.
A Phase II Study of Reirradiation with NBTXR3 in Patients with Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma
This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objectives of the study are: (i) to estimate progression-free survival (PFS) and the early clinical benefit in patients treated with NBTXR3 activated by SBRT re-irradiation, with concurrent pembrolizumab; (ii) to assess the safety profile and estimate the early clinical benefit of NBTXR3 activated by a reduced dose of IMRT or IMPT re-irradiation with concurrent pembrolizumab.
The population includes patients with inoperable, locoregional recurrent head and neck squamous cell carcinoma (HNSCC) or second primary HNSCC, previously treated with definitive radiation therapy and without radiographic evidence of metastases. Patients could be anti-PD-1/L1 nave or non-responders. Up to 80 patients may be treated, with up to 60 in the SBRT cohort and up to 20 in the IMRT/IMPT cohort.
***
About NBTXR3
NBTXR3 is a novel, potentially first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The primary mode of action (MoA) of NBTXR3 is designed to generate increased cellular destruction when activated by radiation therapy without increasing damage to healthy tissues. Subsequently, this cellular destruction also triggers an adaptive immune response.
NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.
Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.
Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.
About NANOBIOTIX: http://www.nanobiotix.comIncorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005910/en/
Nanobiotix
Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835
Investor Relations DepartmentRicky BhajunSenior Manager, Investor Relations+33 (0)1 79 97 29 99
Media Relations
France Ulysse CommunicationPierre-Louis Germain
+ 33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
See the article here:
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer -...
The Healthcare Nanotechnology (Nanomedicine) Market report covers the overview of the market and presents the information on business development, market size, and share scenario. The report also emphasizes on the growth prospects of the global Healthcare Nanotechnology (Nanomedicine) market for the period 2020-2024. The report covers market characteristics for each segmentation across the key regions and country and traces the historic and forecast analysis of the industry. The report covers key vendors their revenue, breakdown by regions, and product demand. Other key details include volume, installed capacity, value chain.
Scope of the Report:
As per the , the healthcare nanotechnology (nanomedicine) market includes products that are nanoformulations of the existing drugs or new drugs or are nanobiomaterials. The market is segmented by its application in the medical field, as drug delivery, biomaterials, active implants, diagnostic imaging, tissue regeneration, and other applications. The market is also segmented by its use in the treatment of diseases, like cardiovascular diseases, oncological diseases, neurological diseases, orthopedic diseases, infectious diseases, and other diseases.<
For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195
Key Market Trends:
The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period
A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.
Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.
North America is Expected to Hold the Largest Share in the Market
In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.
The report provides key statistics on the market status of the Healthcare Nanotechnology (Nanomedicine) Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Healthcare Nanotechnology (Nanomedicine).
Purchase this Report (Price 4250 USD for a single-user license) https://www.industryresearch.co/purchase/14099195
Key Insights of Healthcare Nanotechnology (Nanomedicine) Market:
Healthcare Nanotechnology (Nanomedicine) Market Report Covers Following Points in TOC:
For Detailed TOC Click Here
Contact Us:
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [emailprotected]
Our Other Reports:
Electric Discharge Machine Market Share, Top Manufacturers 2020 Future Growth Rate, Industry Size, Business Strategy, Demand Status by 2026 Research Includes COVID-19 Analysis
Halquinol Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry
GRE Pipes Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry
Copper Cable Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry
Hemodialysis Concentrates & Powders Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry
Closed Cell Elastomeric Foam Market 2020 Share, Segment and Growth Technologies by Company Profiles, Future Scope with Regions, Trends Insights, Global Industry Forecast till 2026
See the original post here:
Healthcare Nanotechnology (Nanomedicine) Market Growth and Demand 2020 Global Industry Segmentation Analysis by Manufacturing Size, Trending Status of...
The Healthcare Nanotechnology (Nanomedicine) Market report 2020 covers all the significant developments which are recently being adopted across the global market. The prime objective of the Healthcare Nanotechnology (Nanomedicine) market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends, and opportunities. The Healthcare Nanotechnology (Nanomedicine) market report covers both the demand and supply aspects of the market. The report also highlighted the future trends in the Healthcare Nanotechnology (Nanomedicine) market that will impact the demand during the forecast period.
Scope of the Report:
As per the , the healthcare nanotechnology (nanomedicine) market includes products that are nanoformulations of the existing drugs or new drugs or are nanobiomaterials. The market is segmented by its application in the medical field, as drug delivery, biomaterials, active implants, diagnostic imaging, tissue regeneration, and other applications. The market is also segmented by its use in the treatment of diseases, like cardiovascular diseases, oncological diseases, neurological diseases, orthopedic diseases, infectious diseases, and other diseases.<
Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14099195
Market Overview:
Some of the Top Key Players of Healthcare Nanotechnology (Nanomedicine) Market Report Are:
Report Highlights:
For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195
Key Market Trends:
The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period
A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.
Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.
North America is Expected to Hold the Largest Share in the Market
In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.
The Report Covers:
Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14099195
Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market Report 2020-2024:
1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Contact Us:
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [emailprotected]
Our Other Reports:
Weight Management Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025
Blockchain Technology Market Development Analysis Contributing Top Vendor Landscape 2020 Global Share & Size, Future Plans by Top Key Players and Economic Growth 2025 with COVID-19 Impact
Unmanned Aerial Vehicle (UAV) Market Development Analysis Contributing Top Vendor Landscape 2020 Global Share and Size, Future Plans by Top Key Players and Economic Growth 2026 with COVID-19 Impact
Sensor ICs Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry
Automotive Structural Sheet Metal Market Growth, Industry Trends 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact
Vitamin D Therapy Market 2020 Share, Segment and Growth Technologies by Company Profiles, Future Scope with Regions, Trends Insights, Global Industry Forecast till 2026
NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN : FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019.
2019 Revenues
In K
Twelve months Ended
December 31st, 2019
Twelve months Ended
December 31st, 2018
Revenues
68
105
Of which licenses
-
-
Of which services
68
99
Other sales
-
6
Revenue for Q4 2019
In K
Q4 2019
Q3 2019
Q2 2019
Q1 2019
Revenues
20
11
32
5
Of which licenses
-
-
-
-
Of which services
20
11
32
5
Activity and results
Nanobiotixs revenue for the fourth quarter amounted to approximatively 20k.
Most of the revenues generated by the Company during this period result from the recharge of costs related to our license and collaboration agreement with PharmaEngine.
Overall, Nanobiotixs annual revenue in 2019 amounted to approximatively 68k.
The amount of cash and cash equivalent as of December 31st, 2019 amounted to 35 094k. This amount does not include the research tax credit related to 2018, normally expected in Q4 which was received in February 2020.
In November 2019, Nanobiotix announced promising results from a pre-clinical immuno-oncology study of NBTXR3 at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In the study, conducted at The University of Texas MD Anderson Cancer Center, researchers studied NBTXR3 activated by radiation therapy in combination with anti-PD-1 treatment in immunocompetent mice. Combination treatment that included NBTXR3 and anti-PD-1 increased local control of the irradiated tumor, generated a marked abscopal effect, decreased the number of spontaneous lung metastases, and significantly increased survival when compared to other treatments in the study, including anti-PD-1 combined with radiation therapy alone. The results indicated that the combination treatment has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.
The study also included an in vivo RadScopal model in which a second tumor received a low dose of radiation while the first tumor received a full dose. In this model, researchers evaluated NBTXR3 activated by radiation therapy combined with anti-PD-1 and anti-CTLA-4 treatment. In the study, combination treatment triggered better local control, along with significant increases in abscopal effect and survival, when compared to all other tested combinations. Several complete responses were observed in the second tumor of the group that received the NBTXR3 combination, while none were observed in the other groups. Nanobiotix believes these results could pave the way for the use of NBTXR3 to improve treatment outcomes for immunooncology patients, including checkpoint inhibitor non-responders.
On December 16th 2019, Nanobiotix received the French 2019 Prix Galien award for Most Innovative MedTech. This award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.
2020 Financial agenda
Nanobiotix plans to announce its financial and operating results as follows:
About NANOBIOTIX: http://www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. The Company also possesses an affiliate, Curadigm, located in Paris, France and Cambridge, MA in the U.S.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005446/en/
Go here to see the original:
Nanobiotix 2019 Q4 and Annual Revenues - BioSpace
Latest Research Report: Oral Contrast Agent industry
This has brought along several changes in This report also covers the impact of COVID-19 on the global market.
Global Oral Contrast Agent Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.
Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/39407
Oral Contrast Agent Market competition by top manufacturers as follow: GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India),
The risingtechnology in Oral Contrast Agentmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.
The Type Coverage in the Market are: Barium-based Contrast MediaIodinated Contrast MediaGadolinium-based Contrast MediaMicrobubble Contrast Media
Market Segment by Applications, covers:Cardiovascular DisordersCancerGastrointestinal DisordersMusculoskeletal DisordersNeurological DisordersNephrological Disorders
The research report summarizes companies from different industries. This Oral Contrast Agent Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.
Oral Contrast Agent is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.
To get this report at a profitable rate.: https://reportsinsights.com/discount/39407
Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa
Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint
Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Oral-Contrast-Agent-Market-39407
About US:
Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.
Contact US:
:(US) +1-214-272-0234
:(APAC) +91-7972263819
Email:[emailprotected]
Sales:[emailprotected]
See the original post:
New Comprehensive Report on Oral Contrast Agent Market to Witness an Outstanding Growth during 2020 2028 with Top Players Like Taejoon Pharm (South...
Market share of global Nanomedicine industry is dominate by companies like Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018).
Access Report Details at: https://www.themarketreports.com/report/global-nanomedicine-market-by-manufacturers-countries-type-and-application-forecast
Market Segment by Regions, regional analysis covers:
Market Segment by Type, covers:
Market Segment by Applications, can be divided into
Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1490823
With the help of 15 chapters spread over 100 pages this report describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Nanomedicine, in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2019 to 2024 is provided in this research report. At last information about Nanomedicine sales channel, distributors, traders, dealers, and research findings completes the global Nanomedicine market research report.
Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1490823
View original post here:
Global Nanomedicine Market Forecast (2019-2024) Report: By Regions, Type and Application with Sales and Revenue Analysis - Editorials 360
The Global Nanomedicine Market research report includes various topics like total industry size, key drivers, challenges, growth opportunities, share, growth, demand, outlook etc. it covers key market updates, the impact of regulations and technological updates.
The report addresses the need to stay updated in this competitive industry conditions and this provides and comprehensive data for making strategies and decision so as to stimulate the market growth and profitability.
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points within the industrys value chain.
No. of Pages: 124
Inquire more or share questions if any before the purchase on Nanomedicine Industry report @https://www.orianresearch.com/enquiry-before-buying/627186
Report Covers Market Segment by Manufacturers: Combimatrix Ablynx Abraxis Bioscience Celgene Mallinckrodt Arrowhead Research GE Healthcare Merck
Market Segment by Type, covers: Quantum dots Nanoparticles Nanoshells Nanotubes Nanodevices
Market Segment by Applications, can be divided into: Segmentation encompasses oncology Infectious diseases Cardiology Orthopedics Others
Order Copy of this Report @https://www.orianresearch.com/checkout/627186
There are 15 Chapters to deeply display the global Nanomedicine market.Chapter 1: Describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force.
About UsOrian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.
Here is the original post:
Nanomedicine Market: 2020 Global Industry Growth Prospects and Insights on Future Scenario | Company Profiles Combimatrix, Ablynx, Abraxis Bioscience,...
The Global Nanomedicine Market (2019 2026) research offers a basic overview of the industry including definitions, applications, classifications, and market chain structure. Moreover, in the global Nanomedicine Market report, the key product categories of the market are included. The report comparably demonstrates supportive data related to the dominant players in the market, for instance, product offerings, segmentation, revenue, and business synopsis. The global Nanomedicine Market is as well analyzed on the basis of numerous regions. The firstly the report describes the market overview, cost structure, upstream, and technology. The second part describes the global Nanomedicine market by key players, by application and type.
Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/nanomedicine-market-ric/505553/request-sample
Competitive Analysis
The global Nanomedicine market report wraps scope and product overview to define the key terms and offers comprehensive information about market dynamics to the readers. This is trailed by the regional outlook and segmental analysis. The report also consists of the facts and key values of the global Nanomedicine market in terms of sales and volume, revenue and growth rate.
One of the important factors in the global Nanomedicine market report is competitive analysis. The report covers all the key factors, such as product innovation, market strategies of the key players, market share, revenue generation, latest research and development, and market expert views.
The followingTopmanufacturersare assessed in this report:
AffilogicLTFNBergmannstrostGrupo PraxisBiotechrabbitBraccoMaterials ResearchCentreCarlina technologiesChemConnectionCIC biomaGUNECIBER-BBNContiproCristal TherapeuticsDTIEndomagneticsFraunhofer ICT-IMMTecnaliaTeknikerGIMACIMDEAIstec CNRSwedNanoTechVicomtechVITO NV
Nanomedicine Market Segmentation
For the better grasp insight of the market, this report has provided a detailed analysis of drivers restraints, and trends that dominate the present market scenario and also the future status of the global Nanomedicine market during the projected period of 2018-2026.
Market Analysis by Product Type
Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery
Market Analysis by End-User Application
Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology
While classifying these segments, the expert team of analysts has listed the relative contribution of each segment for the growth of the global Nanomedicine market. Detail information of segments is required to recognize the key trends influencing the global market for the Nanomedicine.
Each segment of the market provides a piece of in-depth information on the qualitative and quantitative aspects of the market. While giving a brief idea about the revenue opportunities for all the segments, this report has also provided the value of absolute dollar opportunity for all the segments over the predicted period of 2018 2026.
Regional Analysis
The significant regions covered in the reports of the global Nanomedicine market are North America, Europe, the Asia Pacific, South America, and the Middle East and Africa. The market information not only provides the market data of the five geographies as a whole, but it also provides you qualitative as well we qualitative information on country level bifurcation. Adding to that, economic, technological, cultural and social aspects along with the regulatory barriers are entirely analyzed to understand the thorough market scenario across different geographies.
The key highlight of the Research:
Key Questions Answered:
Get In Touch!
Navale ICON IT Park,
Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune
Maharashtra 411041
phone +91-020-67320403
Email help@researchindustry.us
Share
Share
Metal nanoclusters, made up of several to one hundred metal atoms (e.g., Au, Ag, Cu, Pt), are a novel class of intermediate between metal atoms and nanoparticles. As their size (<2 nm) borders on the Fermi wavelength of electrons, metal nanoclusters possess strong photoluminescence in comparison with large metal nanoparticles (>2 nm). This, combined with tunable fluorescence emissions, high photostability, good quantum yields and facile synthesis, make them excellent fluorescent labels for biomedical applications.
However, the reduction of metal ions in liquid solution during synthesis usually causes large nanoparticles rather than small metal nanocluster formation because of their tendency to aggregate. In light of this, proteins whose thiol, amino, and carboxyl groups have a strong affinity for metal atoms are typically used to stabilize metal nanoclusters to protect them from aggregationthese proctected clusters are commonly called protein-protected metal nanoclusters.
Protein-protected metal nanoclusters have excellent biocompatibility and have received considerable attention as a luminescent probe in a number of fields such as biosensing, bioimaging, and imaging-guided therapy. However, apart from unique optical properties, protein-protected metal nanoclusters also possess interesting biological properties such as enzyme-like activity similar to that of natural enzymes; until recently, this has been an overlooked quality that is starting to shine in basic research and practical applications.
Nanozymes is a new termed used to refer to nanomaterials with intrinsic enzyme-like activity. Since professor Yan and coworkers first discovered that nanoparticleswhich are traditionally assumed to be inertpossessed intrinsic enzyme-like activity, a substantial amount of work has focused on further developing and harnessing the advantageous properties of nanozymes, which include high catalytic ability, high stability, and low cost. Nowadays, more than 540 kinds of nanomaterials, which possess intrinsic enzymatic activity, have been reported from 350 laboratories in 30 countries and have been used in biological analysis, environmental treatment, as antibacterial agents, cancer therapy, and antioxidation therapy.
In a recent study published in WIREs Nanomedicine and Nanobiotechnology, Professor Xiyun Yan and Kelong Fan explore the newly developing field of biologically active protein-protected metal nanoclusters, namely those that possess peroxidase, oxidase, and catalase activities, and are consequently used for biological analysis and environmental treatment.
An intriguing example of this is bovine serum albumin-protected gold (Au) nanoclusters, which exhibit peroxidase enzymatic activity to catalyze the oxidation of colored organic substrates, which is currently carried out using natural peroxidases. This method showed an advantage over the natural peroxidase-based methods because bovine serum albumin-protected Au nanoclusters exhibited higher robustness and retained enzymatic activity over a wide range of pH and temperatures. In another example, lysozyme-protected platinum (Pt) nanoclusters exhibit oxidase enzymatic activity which has been applied to the oxidative degradation of pollutants, such as methylene blue in lake water.
The proteins themselves not only provide protection and stabilization during synthesis, but can also provide a myriad of other functions to the nanoclusters. Proteins have been shown to enable in vivo applications because of their enhanced biocompatibility. In fact, a protease-responsive sensor for in vivo disease monitoring was designed by utilizing the peroxidase activity of peptide-protected Au nanoclusters and their ultra-small size dependent tumor accumulation and renal clearance properties.
The sensor was developed using peptides which are the substrates/targets of disease related proteases as protective ligands to synthesis the Au nanoclusters nanozymes, which were then conjugated to a carrier. After reaching the site of disease, the sensor was disassembled in response to the dysregulated protease and the liberated Au nanoclusters were filtered through the kidneys and into urine to produce a rapid and sensitive colorimetric readout of diseases state. By employing different enzymatic substrate as protective ligands for Au nanoclusters, this modular approach could enable the rapid detection of a diverse range of diseases with dysregulated protease activities such as cancer, inflammation, and thrombosis.
These findings have extended the horizon of protein-protected metal nanoclusters properties as well as their application in various fields, says Kelong Fan. Furthermore, in the field of nanozymes, protein-protected metal nanoclusters have emerged as an outstanding new addition. Due to their ultra-small size (<2 nm), they usually have higher catalytic activity, more suitable size for in vivo application, better biocompatibility and photoluminescence in comparison with large size nanozymes. We think that ultra-small nanozymes based on protein-protected MNCs are on the verge of attracting great interest across various disciplines and will stimulate research in the fields of nanotechnology and biology.
Despite the advantages and advancedprogress in the development of protein-protected metal nanoclusters asultra-small nanozymes, there are still some challenges that need to be addressedin future work.
First, most researchers still only rely on bovine serum albumin as both the reducing agent and stabilizer. Since we know that protein-protected metal nanoclusters may retain the bioactivity of the protein ligand, it is necessary to explore methods for synthesizing other new protein-protected metal nanoclusters, which will widen the diagnostic and therapeutic applications of protein-protected metal nanoclusters nanozymes.
Second, there are six types of catalytic reactions in nature: oxidoreductases, transferases, hydrolases, isomerases, ligases, and lyases. Thus far, although many protein-protected metal nanoclusters have demonstrated enzyme activities they all are oxidoreductase-like activities such as peroxidase, oxidase, and catalase. Therefore, there is a ample room to develop other types of nanozymes based on protein-protected metal nanoclusters. In this regard, more understanding of the structures and catalytic mechanisms of protein-protected metal nanoclusters is required in addition to the deeper understanding on natural enzymes themselves.
Third, a considerable number of reports have suggested that ultra-small nanozymes based on protein-protected metal nanoclusters are promising tools for biological analysis. However, little is known about the therapeutic function of these ultra-small clusters in vivo despite their advantages of suitable size and good biocompatibility. It is well known that peroxidase, oxidase, and catalase are main enzymes in biological systems involved in the maintenance of redox homeostasis. Thus, more attention should be paid to the usage of these ultra-small nanozymes based on protein-protected metal nanoclusters as bio-catalysts in various human diseases involved in redox dysregulation such as cancer, inflammation, cardiovascular diseases. It is also possible to employ the products of redox nanozymes to treat other diseases, for example, use the toxic hydroxyl radicals produced by peroxidase nanozymes to treat bacterial infection.
Overall, there is still much room for future research and application of ultra-small nanozymes based on protein-protected metal nanoclusters. It is expected that the enzyme-like activity of protein-protected metal nanoclusters will certainly attract broader interests across various disciplines and stimulate research in the fields of nanotechnology and biology, making these emerging ultra-small nanozymes become novel multifunctional nanomaterials for a number of biomedical applications.
Kindly contributed by the authors.
View original post here:
Protein-Protected Metal Nanoclusters That Behave Like Natural Enzymes - Advanced Science News